Tom Still: Psilocybin research makes for strange political bedfellows – but promise is there

The groundbreaking of the $60 million Usona facility came as the company embarks on a Phase 2 study of psilocybin to treat depression. That study will take place at UW-Madison, Johns Hopkins University, Yale University and other sites. A first-in-human study by Usona is planned for 2022.